汇宇制药(688553.SH)：注射用帕瑞昔布钠、注射用培美曲塞二钠获境外上市许可

Core Viewpoint - The company has received marketing approvals for its injectable products, Parecoxib Sodium and Pemetrexed Disodium, from regulatory authorities in the Netherlands and Saudi Arabia, enhancing its international market presence and product pipeline [1] Group 1: Regulatory Approvals - The company's subsidiary, Seacross Pharma (Europe) Ltd., and Seacross Pharmaceuticals Ltd. have obtained marketing licenses for injectable Parecoxib Sodium and injectable Pemetrexed Disodium from the Dutch Medicines and Medical Devices Authority and the Saudi Food and Drug Authority [1] Group 2: Market Impact - The approvals are expected to enrich the company's product pipeline in international markets, improve its brand image, and facilitate the ongoing expansion of its international business [1] - The developments lay a solid foundation for the sustainable growth of the company in international markets [1]